GLP-1 receptor agonists (GLP-1s) and SGLT-2 inhibitors lower the risk of major cardiovascular events like heart attacks and severe liver complications compared to other diabetes treatments, according to data presented at ENDO 2024. Researchers reviewed Medicare data documented from 2013 to 2020 and a large U.S. health insurance database from 2013 to 2022. They performed...
Children who are sedentary for more than six waking hours a day have a significantly increased risk of severe fatty liver disease and liver cirrhosis by young adulthood, according to a study presented at ENDO 2024 and published in Nature’s npj Gut and Liver. “We found that this relationship between sedentariness and liver damage is likely...
Research published in The Journal of Clinical Endocrinology & Metabolism further shows the unique opportunity endocrinologists are in to manage nonalcoholic liver disease and its various comorbidities. However, without approved pharmaceutical solutions, endocrinologists will have much to offer in treating these ever-increasing conditions. In an October 2022 paper published in The Journal of Clinical...
As obesity rates continue to climb so does metabolic associated fatty liver disease (MAFLD), often at an alarming rate. Endocrine News talks to Theodore C. Friedman, MD, PhD, and Magda Shaheen, MD, PhD, about research they presented at ENDO 2023 on fatty liver disease’s link to diabetes, what impact new medications could have, and how...
Endocrine dysfunction plays a prominent role in the development of steatotic liver disease and was featured prominently with a multi-session program at ENDO 2023. Endocrinologists will be on the front lines to help patients stave off this disorder that will no longer be known as “fatty liver disease,” which is projected to become the leading...
Along with the public health challenges of obesity and diabetes, endocrinologists are now becoming keenly aware of the prevalence of another ominous threat: non-alcoholic steatohepatitis (NASH). Endocrine Society members Abhinav Seth, MD, PhD, and Roberto Calle, MD, both with Regeneron, give Endocrine News an exclusive primer on this disorder, as well as a future path...
Women with long or irregular periods are known to have a higher risk of type 2 diabetes and heart disease, but researchers found these women may also be at risk for nonalcoholic fatty liver disease (NAFLD), according to a new study published in The Journal of Clinical Endocrinology and Metabolism. About 24% of U.S. adults have...
As obesity rates continue to climb so does metabolic associated fatty liver disease (MAFLD), often at an alarming rate. Endocrine News talks to Theodore C. Friedman, MD, PhD, and Magda Shaheen, MD, PhD, about research they presented at ENDO 2023 on fatty liver disease’s link to diabetes, what impact new medications could have, and how...
